Literature DB >> 22406382

Acute hemodynamic response to biventricular pacing in heart failure patients with narrow, moderately, and severely prolonged QRS duration.

Sylvain Ploux1, Zachary Whinnett, Joost Lumens, Arnaud Denis, Adlane Zemmoura, Maxime De Guillebon, Khaled Ramoul, Philippe Ritter, Pierre Jaïs, Jacques Clementy, Michel Haïssaguerre, Pierre Bordachar.   

Abstract

BACKGROUND: The efficacy of biventricular (BiV) pacing in patients with a narrow or moderately prolonged QRS duration remains questionable.
OBJECTIVE: To assess the hypothesis that electrical dyssynchrony is required to obtain hemodynamic benefit from BiV pacing by investigating the relationship between intrinsic QRS duration and hemodynamic response to BiV pacing in a patient population covering a broad spectrum of QRS duration.
METHODS: Eighty-two consecutive heart failure patients underwent cardiac resynchronization therapy implantation irrespective of their QRS duration. Thirty-four patients had a narrow QRS duration (<120 ms), whereas 11 patients had a moderately prolonged QRS duration (≥120 to <150 ms) and 37 patients had a severely prolonged QRS duration (≥150 ms). After implantation, invasive left ventricular (LV) dP/dt measurements were compared between intrinsic rhythm and simultaneous BiV pacing with an optimized atrioventricular delay.
RESULTS: A high correlation (r = .65; P < .001) was observed between baseline QRS duration and changes in LV dP/dt(max) induced by BiV pacing. BiV pacing was ineffective in patients with a narrow QRS duration (+0.4% ± 6.1%; P = ns). No significant increase in LV dP/dt(max) was observed in patients with a QRS duration of ≥120 to <150 ms (+4.4% ± 6.9%; P = .06), whereas patients with a QRS duration of ≥150 ms exhibited a significant increase in LV dP/dt(max) (+17.1% ± 13.4%; P <.001). Only 9% of the patients with a narrow QRS duration exhibited a ≥10% increase in LV dP/dt(max).
CONCLUSIONS: Baseline QRS duration is linearly related to acute hemodynamic response to BiV pacing. Patients with a narrow QRS duration do not derive hemodynamic improvement. This improvement is also limited in patients with a moderately prolonged QRS duration, raising questions about the potential clinical benefit of this therapy in these patients.
Copyright © 2012 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22406382     DOI: 10.1016/j.hrthm.2012.03.016

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  4 in total

1.  Novel measure of electrical dyssynchrony predicts response in cardiac resynchronization therapy: Results from the SMART-AV Trial.

Authors:  Larisa G Tereshchenko; Alan Cheng; Jason Park; Nicholas Wold; Timothy E Meyer; Michael R Gold; Suneet Mittal; Jagmeet Singh; Kenneth M Stein; Kenneth A Ellenbogen
Journal:  Heart Rhythm       Date:  2015-08-10       Impact factor: 6.343

2.  Usefulness of the Sum Absolute QRST Integral to Predict Outcomes in Patients Receiving Cardiac Resynchronization Therapy.

Authors:  Jonatan Jacobsson; Rasmus Borgquist; Christian Reitan; Elyar Ghafoori; Neal A Chatterjee; Muammar Kabir; Pyotr G Platonov; Jonas Carlson; Jagmeet P Singh; Larisa G Tereshchenko
Journal:  Am J Cardiol       Date:  2016-05-14       Impact factor: 2.778

3.  [Management of heart failure with His bundle pacing in right bundle branch block: case report].

Authors:  Jorge Gómez-Flores; Jovana Pérez-Báez; Guillermo Muñoz; Gabriela Bustillos-García; Alan García; Álvaro E Reyes-Quintero; Rosa M Ávila-Ocampo; Antonio Arias-Godínez; Manlio Márquez; Luis Colin-Lizalde; Moisés Levinstein-Jacinto; José L Morales-Velázquez; Santiago Nava
Journal:  Arch Cardiol Mex       Date:  2021

4.  Long-term outcomes of left bundle branch area pacing versus biventricular pacing in patients with heart failure and complete left bundle branch block.

Authors:  Juan Hua; Yang Chen; Jianhua Yu; Qinmei Xiong; Zhen Xia; Zirong Xia; Qianghui Huang; Qiling Kong; Huolong Chen; Yichu Zhang; Jianxin Hu; Juxiang Li; Jinzhu Hu; Qi Chen; Kui Hong
Journal:  Heart Vessels       Date:  2022-01-28       Impact factor: 1.814

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.